Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
Tiziana Life Sci Plc (TILS.L) Appointment of Chief Medical Officer
Tiziana Life Sci PLC (TILS.L) to Present at Biotech Showcase Digital 2021
NEW YORK and LONDON – 11 January 2021 (GLOBE NEWSWIRE) – Tiziana Life Sciences plc (NASDAQ: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative
Tiziana Life Sci PLC (TILS.L) Completion of Foralumab Clinical Trial in Brazil
Tiziana announces completion of the clinical trial with nasally administered Foralumab, its proprietary fully human anti-CD3 monoclonal antibody, for the treatment of COVID-19 patients in Brazil
Tiziana Life Sci PLC (TILS.L) Phase 1b/2 Clinical Trial – Crohn’s Disease
Phase 1b/2 Clinical Trial – Crohn’s Disease
Tiziana Life Sci PLC (TILS.L) Initiation of Clinical Trial for COVID-19 Patients
Tiziana Announces Initiation of Clinical Trial for COVID-19 Patients in Brazil with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody
Tiziana Life Sci (TILS.L) Exercise of options, Issue of Equity, PDMR Dealing
London, New York, 26 October 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for oncology, inflammation
TIZIANA LIFE SCI PLC (TILS.L) Result of General Meeting
At the General Meeting of the Company held at 11.00 a.m. on 2 October 2020, both of the resolutions were duly passed.
TIZIANA LIFE SCI PLC (TILS.L) Interview – Bloomberg International
Tiziana Life Sciences Interview to Air on Bloomberg International on the RedChip Money Report
Tiziana Life Sci PLC (TILS.L) Publication of Research Note
London, New York, 21 September 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) (“Tiziana” or the “Company”), is pleased to note the publication of a new analyst
Tiziana Life Sci PLC (TILS.L) Clinical Study with Nasally Administered Foralumab
Tiziana to Conduct a Clinical Study with Nasally Administered Foralumab, a Fully Human Anti-CD3 Monoclonal Antibody, for Treatment of COVID-19 Patients in Brazil
Tiziana Life Sci PLC (TILS.L) Demerger of StemPrintER and Distribution in Specie
Demerger of StemPrintER and Distribution in Specie Proposed capital reduction and notice of General Meeting
